American Society of Hirudotherapy

Microvascular ear replantation: a multicenter study of 22 patients with complete ear amputation

Multicenter study published in Facial Plast Surg Aesthet Med (2021)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Observational studyClinical LiteratureJiang Y et al. · Facial plastic surgery & aesthetic medicine, 2024

Abstract

Background: We aimed to report our experience in treating ear amputations with microvascular replantation, with the largest sample to date. Methods: Twenty-two patients with complete ear amputation underwent microvascular ear replantation at three medical centers between May 2003 and May 2020. Arterial anastomoses, venous anastomoses, or vein graft were performed depending on different situations. Re-exploration was performed in four patients due to venous congestion (n = 3) or arterial compromise (n = 1). Results: Eleven patients had vascular complications (venous congestion: 10, arterial compromise: 1) and four of them required re-exploration. Three ears were completely salvaged (75%) and one case failed. Eighteen (81.8%) replanted ears survived completely, with 15 repaired ears demonstrating a good contour and 3 ears showing atrophy. Three replanted ears sustained partial loss, and one sustained total loss. Three extraordinary cases with the longest ischemic time, smallest tissue size, and youngest age reported thus far all survived and had cosmetically satisfactory appearances. Statistical analysis indicated no significant correlation between replanted ear survival and potentially influential factors, including ischemic time, number of arterial and venous anastomoses, presence of vein graft, and re-exploration. Conclusions: Microvascular replantation for ear amputations achieved excellent results. It may be considered the primary choice for surgeons with microsurgical skill.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleMulticenter StudyResearch Support, Non-U.S. Gov't
Indexed MeSH termsHumansReplantationMaleFemaleAdultAmputation, TraumaticMiddle AgedAdolescentMicrosurgeryEar, ExternalYoung AdultChildRetrospective StudiesTreatment OutcomeAnastomosis, Surgical

Summary

In the largest reported series to date, 22 patients with complete ear amputation underwent microvascular ear replantation at three medical centers; 18 (81.8%) replanted ears survived completely, and 11 patients had vascular complications, including 10 with venous congestion.

Context

This multicenter study reports outcomes of microvascular ear replantation in 22 patients with complete ear amputation, achieving an 81.8% complete survival rate. Venous congestion was the most common vascular complication (10 of 22 patients). The study makes no mention of leech therapy or hirudotherapy. While ear replantation complicated by venous congestion is a clinical scenario where medicinal leeches are sometimes employed adjunctively, this study does not describe any leech-related intervention. The study is set within the surgical context where venous congestion management challenges arise. The focus is on surgical technique and outcomes rather than adjunctive congestion therapies.

Citation

Reference (Vancouver style)

Jiang Y, Li L, Huang L, Xie A, Liu L, Sun W. Microvascular ear replantation: a multicenter study of 22 patients with complete ear amputation. Facial Plast Surg Aesthet Med. 2024;26(4):437-443. doi:10.1089/fpsam.2021.0062. PMID: 34516927

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.